These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31543688)

  • 1. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
    Choe WH; Kim K; Lee SY; Choi YM; Kwon SY; Kim JH; Kim BJ
    World J Gastroenterol; 2019 Sep; 25(33):4985-4998. PubMed ID: 31543688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
    Sayan M; Buğdacı MS
    Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
    Kırdar S; Yaşa MH; Sayan M; Aydın N
    Mikrobiyol Bul; 2019 Apr; 53(2):144-155. PubMed ID: 31130119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
    Jiang B; Dai CY; Li XM; Su R; Xu J; Cao Y; Hou W; Lu W
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jan; 24(1):36-9. PubMed ID: 26983387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
    Gomes-Gouvêa MS; Ferreira AC; Teixeira R; Andrade JR; Ferreira AS; Barros LM; Rezende RE; Nastri AC; Leite AG; Piccoli LZ; Galvan J; Conde SR; Soares MC; Kliemann DA; Bertolini DA; Kunyoshi AS; Lyra AC; Oikawa MK; de Araújo LV; Carrilho FJ; Mendes-Corrêa MC; Pinho JR
    Antivir Ther; 2015; 20(4):387-95. PubMed ID: 25624410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
    Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
    J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
    Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
    World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of real time allele specific locked nucleic acid quantitative PCR for detection of HBV YIDD (ATT) mutation and evaluation of its application.
    Zeng Y; Li D; Wang W; Su M; Lin J; Chen H; Jiang L; Chen J; Yang B; Ou Q
    PLoS One; 2014; 9(2):e90029. PubMed ID: 24587198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
    Zhao Y; Wu J; Sun L; Liu G; Li B; Zheng Y; Li X; Tao J
    Braz J Infect Dis; 2016; 20(2):173-8. PubMed ID: 26876337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
    Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F
    J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in Pol gene of hepatitis B virus in patients with chronic hepatitis B before and after therapy with nucleoside/nucleotide analogues.
    Januszkiewicz-Lewandowska D; Rucka A; Kowala-Piaskowska A; Bereszynska I; Mozer-Lisewska I; Zajac-Spychala O; Wysocki J; Nowak J
    Acta Virol; 2014; 58(2):185-9. PubMed ID: 24957725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.